{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:47:17Z","timestamp":1792432037382,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR003096"],"award-info":[{"award-number":["UL1TR003096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK072482"],"award-info":[{"award-number":["DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20A0-KB"],"award-info":[{"award-number":["GUIMBE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019192","name":"Center for Clinical and Translational Science, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["UL1TR003096"],"award-info":[{"award-number":["UL1TR003096"]}],"id":[{"id":"10.13039\/100019192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pupt.2024.102301","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:15:57Z","timestamp":1716556557000},"page":"102301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacokinetic variability of CFTR modulators from standard and alternative regimens"],"prefix":"10.1016","volume":"86","author":[{"given":"Natalie R.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashritha R.","family":"Chalamalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Krick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Schellhase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2024.102301_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2014.06.005","article-title":"New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls","volume":"145","author":"Bell","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pupt.2024.102301_bib2","first-page":"59","article-title":"Pulmonology: CFTR modulators for cystic fibrosis","volume":"26","author":"Bertoncini","year":"2013","journal-title":"J. Am. Acad. Physician Assistants"},{"issue":"127","key":"10.1016\/j.pupt.2024.102301_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1183\/09059180.00008412","article-title":"Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"22","author":"Derichs","year":"2013","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2024.102301_bib4","author":"Administration"},{"key":"10.1016\/j.pupt.2024.102301_bib5","series-title":"Drug Approval Package: Kalydeco (Ivacaftor)","author":"Administration","year":"2012"},{"issue":"18","key":"10.1016\/j.pupt.2024.102301_bib6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2024.102301_bib7","series-title":"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis","year":"2018"},{"issue":"7","key":"10.1016\/j.pupt.2024.102301_bib8","article-title":"A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.pupt.2024.102301_bib9","first-page":"3","article-title":"CFTR modulator therapies - effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr. Respir. Rev."},{"issue":"6","key":"10.1016\/j.pupt.2024.102301_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2024.102301_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.pupt.2024.102301_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.pupt.2024.102301_bib13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.pupt.2024.102301_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pupt.2024.102301_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.pupt.2024.102301_bib16","article-title":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"16","author":"Vonk","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102301_bib17","unstructured":"Administration FaD. Trikfata: Regulatory Review 2019 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf."},{"issue":"2","key":"10.1016\/j.pupt.2024.102301_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"issue":"1","key":"10.1016\/j.pupt.2024.102301_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.pupt.2024.102301_bib20","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ppul.26093","article-title":"Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis","volume":"57","author":"Guimbellot","year":"2022","journal-title":"Pediatr. Pulmonol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:38:24Z","timestamp":1778798304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553924000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"alternative-id":["S1094553924000178"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102301","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102301"}}